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Background: Latest World Health Organization guidelines
recommend shifting away from Stavudine (d4T)-based regimens
due to severe side effects. However, widespread replacement of d4T
by Tenofovir (TDF) or Zidovudine (AZT) is hampered by cost
concerns.
Methods: We established the cost-effectiveness of alternative ﬁrst-
line regimens using primary utilization, cost, and outcome data from
a program in a rural district in Lesotho. We calculated cost per
patient-year, incremental costs, and incremental cost-effectiveness
ratios per life year, and per Quality Adjusted Life Year gained.
Uncertainty was assessed using multiway and probabilistic sensitivity
analyses.
Results: Our study included 1260 patients representing 1635 patient-
yearsonantiretroviraltherapy(ART).Sixhundredeightpatientswereon
TDF,290wereonAZT,and362wereond4T.Patientsond4Texperienced
more toxicities; toxicities with the biggest impact on quality of life were
moderateneuropathyandseverelipodystrophy.Thecostper patient-year
ranged from US $266 on d4T to US $353 on TDF. Inpatient care and
essentialdrugcostswerehigherfor patientsond4TthanonAZTorTDF.
Incremental cost-effectiveness ratio results suggest that AZT-based ART
is weakly dominated by a combination of d4T- and TDF-based ART.
Discussion: This is one of the ﬁrst analyses to investigate the cost-
effectiveness of TDF using primary data in a resource-poor setting.
Although TDF-based ﬁrst-line ART is more costly than d4T, it is also
more effective. Political pressure should be exerted to encourage
further price reductions and additional generic manufacturing for
TDF and partner drugs such as Efavirenz. This should be met by
a commitment from donors and implementers to ensure that supply is
met by a clear demand.
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INTRODUCTION
The latest World Health Organization guidelines for
antiretroviral therapy in resource-limited settings released in
2009 recommend a shift away from Stavudine (d4T)-based
ﬁrst-line regimens due to the severe, sometimes life-
threatening side effects associated with this drug.
1 The use
of d4T in Western settings began to decline as early as 2000,
and current guidance in Europe states that d4T should only be
used as a last resort.
2 Zidovudine (AZT) has been recom-
mended by World Health Organization guidelines since 2002.
The potential role of Tenofovir (TDF) in ﬁrst-line has been
acknowledged since 2003, although limited availability and
high cost were acknowledged as constraints. TDF was ﬁnally
recommended as a ﬁrst-line option in 2006.
3 An additional
advantage of TDF is its availability as a once-daily regimen,
which is supportive of improved adherence.
4
Despite these advantages, the widespread replacement
of d4T by TDF or AZT is hampered by cost considerations:
d4T remains the cheapest of the 3 drugs, in terms of cost per
daily dose, and major donors continue to resist supporting the
full elimination of d4T. As of July 2010, 14 of 52 developing
countries surveyed by World Health Organization had yet to
start phasing out from d4T to TDF or AZT.
5
Modeled cost-effectiveness analyses have suggested
that, once related costs such as laboratory monitoring
requirements and side-effect management are taken into
account, the cost-effectiveness of TDF would be more
favorable. In India, TDF was found to be more cost-effective
than d4T (ie, same overall costs, but higher outcomes).
6
Another modeled study based in South Africa indicated that
the price of TDF would need to fall from US $17 to US $6.17
per month for TDF to have the same overall cost as d4T-based
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7 However, cost-effectiveness
estimates using primary cost and outcome data from routine
programs are lacking.
The aim of this study was to assess the cost-effectiveness
of TDF versus AZT- and d4T-based ﬁrst-line regimens from
the health system’s perspective based on primary patient-level
data collected within an observational cohort in rural Lesotho.
METHODS
Study Setting and Treatment Strategies
All data included in this study were collected in Lesotho,
a poorly resourced country landlocked by South Africa, with
the third highest HIV prevalence in the world (23% general
adult prevalence). In 2006, Me ´decins Sans Frontie `res and the
Ministry of Health and Social Welfare established a primary
care HIV/AIDS care and treatment program in the Scott
Catchment Area (population 200,000). ART services began in
March 2006, and by the beginning of 2010 the program had
enrolled 6081 patients on ART. Treatment is provided across
14 primary health care centers and 1 district hospital.
8
When ART was initiated in Scott district, the standard
ﬁrst-line treatment included either d4T or AZT for pregnant
women as the nucleoside reverse transcriptase inhibitor
(NRTI) together with Lamivudine (3TC) as the second NRTI
and either Nevirapine (NVP) or Efavirenz (EFV) as the non-
NRTI. Due to the high rate of tuberculosis (TB) coinfection,
EFV is more commonly prescribed than NVP, except for
women of childbearing age who are not using contraception or
are in the ﬁrst trimester of pregnancy. In late 2007, the
Ministry of Health and Social Welfare of Lesotho introduced
TDF as an alternative to d4T or AZT in the ﬁrst-line regimen.
Implementation of the new guideline followed a phased
approach, resulting in the concurrent use of all 3 ﬁrst-line
NRTIs during 2008. AZT was still chosen as the NRTI of
choice for pregnant women and TDF was prescribed in
combination with EFV to enable a once-daily regimen.
As it is not possible to treat a whole population with
a single ﬁrst-line regimen due tovarious exclusion criteria, this
analysis evaluates the cost-effectiveness of 3 possible ﬁrst-line
prescribing options. Option I is a d4T-based regimen (with an
alternative of AZT for women who became pregnant); option
II is an AZT-based regimen (with TDF for patients with
hemoglobin [Hb] ,8 g/dL and d4T for those with creatinine
clearance ,50 ml/min); option III is a TDF-based regimen
(with AZT for pregnant women and/or those with creatinine
clearance ,50 ml/min and d4T Hb ,8 g/dL). In this article,
when we refer to d4T, AZT, or TDF, it refers to the results for
patients who are receiving 1 of these drugs. On the other hand,
when we refer to, for example, a d4T-based ﬁrst-line regimen,
then it implies that patients will be predominantly on d4T-
based ART, but alternative regimens will be prescribed for
patients with exclusions for d4T.
Study Design
This study established the cost-effectiveness of alterna-
tive ﬁrst-line regimens from the health system perspective
using primary resource utilization, cost, and outcome data.
The study cohort included all patients starting on ART during
2008, with follow-up until the end of 2009. Both costs and
outcomes are expressed per patient-year on ART.
Costs, calculated from the health system’s perspective,
include antiretrovirals (ARVs), other essential medicines,
inpatient care, laboratory investigations, counseling, cotrimox-
azole prophylaxis, and nurse consultations. Costs are expressed
in 2009 prices converted to US $ according to the exchange rate
at that time (US $ 1 = 9.76 maloti; http://www.xe.com/ucc/,
accessed 01 December 2009). Outcomes are expressed as life
years and Quality Adjusted Life Years (QALYs). Key results
include the cost per patient-year, outcomes per patient-year,
incremental costs, and incremental cost-effectiveness ratios
(ICER). The ICER for the most effective/costly option is
calculated as the ratio of the incremental costs of this option
versus less costly options divided by the associated incremental
outcomes.Ifone optionhas a higherICER thana moreeffective
strategy, it is said to be weakly dominated by a combination of
the remaining 2 strategies.
9 Given that the analysis was
restricted to a 1-year period, discounting was not undertaken.
Given that the analysis was based on routine clinical
data, ethical review and individual patient consent were not
sought. All patient information was entered into a database
using coded identiﬁcation numbers, and no information that
could reveal patient identity was collected.
Cost per Patient-Year
Cost results are expressed as the cost per patient-year by
drug (ie, d4T, AZT, TDF), and within each of the ﬁrst-line
ART options (ie, d4T-based ART, AZT-based ART, and TDF-
based ART). These were calculated by multiplying the
utilization of a full range of HIV-related services with the
associated unit costs.
Utilization estimates included nurse and counselor
consultations, inpatient days, laboratory tests (CD4 counts,
alanine aminotransferase, creatinine, Hb and sputum smear for
TB), essential drugs including cotrimoxazole prophylaxis, and
ARVs (including d4T, AZT, TDF, 3TC, EFV, and NVP
depending on the ﬁrst-line regimen). These utilization
estimates were extracted from clinic ﬁles by a clinician and
a researcher with experience in cost analysis; all hospital-
izations documented from the clinic were cross-checked
against hospital admission notes. Utilization estimates are
expressed as the mean (with 95% conﬁdence or uncertainty
intervals) per patient-year, by drug.
A nonpatient-speciﬁc unit cost per consultation or per
inpatient day was then established (this is the unit cost stripped
of any items that could be directly attributed to patients,
including all medicines and laboratory investigations). The
cost per nurse and counselor consultation was calculated using
routine accounting information from 6 ART clinics based in
1 hospital outpatient department and 5 primary care facilities.
Costs included the full cost of employment of nurses and
a share offacility running costs (administrative staff, transport,
and other overheads). The cost per nurse or counselor
consultation was estimated by dividing these total costs by
the total number of visits during the same period. Similarly, the
cost per inpatient day at the hospital included the cost of
employment of all staff and hospital running costs, split
equally between inpatients.
9
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consultation and inpatient costs were estimated by establishing
the medicine costs associated with treating the most common
side effects and HIV-related infections and events. Side effects
include neuropathy, lipodystrophy, rashes, lactic acidosis,
anemia, and renal toxicity, whereas HIV-related infections
include cryptococcal meningitis, diarrhea, oral or genital
herpes, oral or esophageal candida, pneumocystis carinii
pneumonia, rashes, respiratory tract infections, TB, and
toxoplasmosis. Medicine costs were calculated by establishing
a standard protocol of medicines to treat the identiﬁed side
effects and HIV-related infections. The cost per patient-year of
each medicine protocol was then established by multiplying
the incidence of each side effect or infection by the medicine
cost of treatment.
ARV costswere based on actual prices obtained from the
Clinton Foundation during 2009. The cost per laboratory
investigation included reagents and consumables, a share of
the cost of employment of laboratory staff, running costs, and
the cost of specimen collection. Finally, costs associated with
training, supervision, and clinical mentorship included the
cost of employment of a doctor, nurse and the associated
transport costs. These were split equally between all patients
on ART to calculate a cost per patient-year. Additional details
are available in Supplemental Digital Content 1
(http://links.lww.com/QAI/A197).
Outcomes per Patient-Year
Outcomes include life years and QALYs. Mortality out-
of-facility was reported to clinic staff by relatives, village
leaders, community health workers, and facility TB/HIV lay
counselors who undertake defaulter tracing. Defaulter tracing is
donewithinafewdaysofapatientmissinganappointmentsuch
that early mortality among those lost to follow-up is
documented within a month of a missed appointment.
Kaplan–Meier estimates were used to calculate rates of death
and defaulting stratiﬁed by drug and time on ART (0–3, 3–6
months, and 6–12 months). Patients were censored when they
were transferred to another ART program or at the end of 2009.
We developed avisual analog scale to assess decrements
in health-related quality of life (HRQoL) associated with the
common adverse events related to d4T, AZT, and TDF. This
scale, which was developed by clinical staff and revised
after piloting, included the following side effects: anemia
(Hb , 8 g/dL); severe neuropathy (symptoms not controlled
by analgesia and requiring a switch in ARV); moderate
neuropathy (symptoms controlled through daily analgesia);
mild neuropathy (slight pins and needles in hands and feet);
severe lipodystrophy (patient feels very stigmatized by
appearance requiring a switch in ARV), mild lipodystrophy
(patient not affected by appearance); severe lactic acidosis
(patient has abdominal pain, vomiting, and breathlessness
requiring a switch in ARVs); mild lactic acidosis (slight
abdominal pain and possible slight weight loss); and renal
toxicity (creatinine clearance between 30 and 50). In the scale,
a 0 value is equivalent to death whereas a value of 1 is
equivalent to perfect health. The resulting median HRQoL
weight was used to estimate QALYs by applying this
decrement over the duration of each of the adverse events
encountered in our sample of patients. Avalueof 1 was applied
to periods where there were no toxicities, and a 0 value was
applied to patients who had died or were lost to follow-up from
the time that these events were recorded.
Uncertainty and Sensitivity Analyses
There are 3 sources of uncertainty that are relevant to this
study: the data set, generalizability of results, and the choice of
analytical methods (eg, valuation of outcomes).
10 Uncertainty
relating to the data has been assessed using probabilistic
sensitivity analysis. Where possible, distributions (uncertainty
intervals) were speciﬁed on utilization, incidence, and outcome
variables, and uncertainty was captured by running 100,000
second-orderMonte Carlo simulations. During eachsimulation,
a different value is sampled from within each uncertainty
interval. When a number of simulations are run, parameter
uncertainty is captured as uncertainty intervals around overall
costs,outcomes, and ICERs.To assessuncertainty inour choice
of analytical methods, we have expressed outcomes as both life
years and as QALYs. We have not assessed uncertainty
associated with discounting as the time horizon of this study
precluded any need for discounting. Finally, we have sought to
strengthen the generalizability of our results through additional
multiway simple sensitivity analyses. First, we have run
a scenario where EFV is substituted for NVP. Second, we have
run a scenario varying the costs of treating toxicities and
HIV-related infections. These scenarios increase the generaliz-
ability of our results (1) to settings where EFV is routinely
prescribed instead of NVP within ﬁrst-line regimens and (2) to
settings where access to inpatient care and where the medicine
costs of treating toxicities and HIV-related infections might
differ from rural Lesotho. All sensitivity analyses were run in
TreeAge Pro 2006.
RESULTS
Our study included 1260 patients representing 1635
patient-years on ART. Six hundred eight patients were on TDF,
290 were on AZT, and 362 were on d4T. Median CD4 at
treatment initiation was215 cells/mm
3 (interquartile ratio 125–
289) and two thirds (66%) of patients were women. Median
time on ARTwas 508 days. Patient characteristics according to
treatment regimen at initiation are shown in Table 1.
The unit costs of the key resources used to manage
a patient on ARTand the utilization of these services/resources
are summarized in Table 2. The latter in addition contains the
uncertainty intervals around the mean estimates per patient-year
that are used within the probabilistic sensitivity analysis. There
were no signiﬁcant differences in consultations and inpatient
days between regimens, and similar quantities of laboratory
investigations were also performed. There was, however, a key
difference in terms of the proportion of patients prescribed EFV
together with TDF (99.8% versus 41.1% and 48.2% in d4Tand
AZT, respectively). Given that EFV costs more than NVP, the
higher utilization of this drug will have implications for the
overall incremental cost of the TDF regimen relative to d4Tand
AZT. In addition, Table 2 gives a breakdown of the cost per
patient-year,byARV ,rangingfromUS$266ond4TtoUS$353
on TDF. The highest share of costs was for ARVs, followed by
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drug costswere higherfor patients ond4T than on AZTor TDF.
Supplemental Digital Content 2
(http://links.lww.com/QAI/A198) summarizes the costs of
essential drugs needed to manage key side effects and HIV-
related infections. The cost differs depending on whether the
episode is managed on an outpatient or an inpatient basis.
These, together with the incidence of these events per patient-
year, give a mean cost per patient-year in each regimen.
Although the highest costs per patient-year were for patients
receiving d4T, in general these costs were very low.
As expected, patients on d4T experienced sig-
niﬁcantly more toxicities than the patients on the
other ARVs (see Supplemental Digital Content 3,
http://links.lww.com/QAI/A199). Results from the visual
analog scale suggest that the lowest HRQoL was associated
with severe lactic acidosis. However, the impact of toxicity on
overall HRQoL will depend on the amount of time for which it
is experienced. The annual HRQoL weight takes this duration
into account by assuming that the patient is returned to perfect
health once the toxicity has been resolved. This calculation
indicates that the toxicities with the biggest impact on annual
HRQoL are moderate neuropathy and severe lipodystrophy.
Table 3 summarizes the cost per patient-year, outcomes,
and ICERs by ﬁrst-line option. Because it is not possible to
treat a whole population with a single regimen, these results
reﬂect the distribution of patients between regimens based
on the characteristics of the cohort. Results indicate that the
TABLE 1. Characteristics of Patients According to Treatment Regimen at Initiation
Total (N = 1260) d4T (N = 362) AZT (N = 290) TDF (N = 608)
CD4 (median, IQR) 214.5 (125–289) 195 (104–279.5) 240 (157–310) 213 (119–283)
Age (median, IQR), years 38 (29–48) 39 (28–50) 33 (26–45) 29 (32–48)
Women, N (%) 831 (66.0) 264 (72.9) 247 (85.2) 320 (52.6)
Follow-up (days) (median, IQR) 508 (398–608) 547 (410–635) 518 (378–587) 494 (400–595)
TB, N (%) 216 (17.1) 62 (17.1) 38 (13.1) 116 (19.1)
IQR, interquartile ratio.
TABLE 2. Unit Costs (US $), Utilization per Patient-Year, and Cost per Patient-Year (US $) by ARV
Unit Cost/Price d4T AZT TDF
Cost per Patient-Year
d4T AZT TDF
Health services Per unit Utilization per patient-year 50.32 46.34 48.15
Inpatient days (mean, 95% UI) 43.32 0.33 (0.11–0.55) 0.23 (0.05–0.42) 0.28 (0.13–0.43) 14.30 10.11 12.13
Nurse consultations (mean, 95% UI) 2.96 12.17 (11.91–12.43) 12.24 (11.81–12.67) 12.17 (11.91–12.43) 36.02 36.23 36.02
Laboratory tests Per unit Utilization per patient-year 19.63 21.75 19.95
AFB (mean, 95% UI) 2.13 0.43 (0.35–0.52) 0.36 (0.27–0.45) 0.26 (0.21–0.31) 0.92 0.77 0.55
CD4 count (mean, 95% UI) 6.62 1.96 (1.89–2.04) 2.01 (1.92–2.09) 2.02 (1.97–2.07) 12.98 13.31 13.37
HB (mean, 95% UI) 2.32 1.10 (1.03–1.16) 2.05 (1.93–2.18) 1.01 (0.97–1.05) 2.55 4.76 2.34
ALT (mean, 95% UI) 1.01 1.89 (1.79–1.99) 1.75 (1.65–1.85) 1.46 (1.40–1.51) 1.91 1.77 1.47
Creatinine (mean, 95% UI) 1.19 1.05 (0.97–1.14) 0.98 (0.88–1.08) 1.86 (1.81–1.91) 1.25 1.17 2.21
Antiretrovirals Per patient-year Proportion per patient-year 75.79 146.24 177.69
TDF 3TC EFV 177.71 — — 99.8% — — 177.35
TDF 3TC NVP 170.04 — — 0.2% — — 0.34
AZT 3TC EFV 156.47 — 48.2% — — 75.42 —
AZT 3TC NVP 136.73 — 51.8% — — 70.83 —
d4T 3TC EFV 97.07 41.1% — — 39.90 — —
d4T 3TC NVP 60.94 58.9% — — 35.89 — —
Essential medicines Per patient-year Proportion per patient-year 10.89 7.69 6.86
Cotrimoxazole prophylaxis 5.75 100% 100% 100% 5.75 5.75 5.75
Essential medicines for
HIV-related infections and toxicities
* * * * 5.14 1.94 1.11
Program-level costs Per patient-year Proportion per patient-year 100.71 100.71 100.71
Supervision 85.95 100% 100% 100% 85.95 85.95 85.95
Counseling 14.76 100% 100% 100% 14.76 14.76 14.76
Total 257.34 322.73 353.37
*See Supplemental Digital Content 2 (http://links.lww.com/QAI/A198) for additional details.
UI, uncertainty interval; MSF, Me ´decins Sans Frontie `res; ALT, alanine aminotransferase.
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positive outcomes per patient-year but also with higher costs
(as indicated by the uncertainty intervals around costs
calculated using probabilistic sensitivity analysis). The ICER
results suggest that the AZT-based regimen is weakly
dominated by a combination of d4T- and TDF-based ART.
The ICER for TDF was higher when outcomes were expressed
as life years. This is because the QALY measure captures both
length of life and the improved HRQoL associated with the
lower incidence of toxicities in patients on TDF.
Results of the 2 multiway sensitivity analyses are
presented in Figures 1 and 2. Although we varied the costs of
inpatient care and essential medicines to treat toxicities and
HIV-related infections over a wide range (from a 50%
reduction in costs to a 200% increase), the percentage change
in overall costs was small. In addition, because all ﬁrst-line
regimens make use of these resources (albeit to varying
extents), any change in these items has a small impact on the
relative cost-effectiveness of regimens. On the other hand, we
ran a scenario where all patients were assumed to receive EFV
instead of NVP. Because EFV is more costly than NVP, and
because close to 100% of those on TDF receive EFV in
comparison with 41% and 48% on d4T or AZT (Table 2),
variations in the usage of EFV will have an impact on the
incremental costs and cost-effectiveness of TDF relative to the
other regimens. Under the baseline scenario, TDF-based ART
costs US $84 more than d4T-based ART, whereas under the
EFV scenario, the difference is US $66, which amounts to
a 22% reduction in these cost differences.
DISCUSSION
In our routine program we found that TDF was
associated with a lower rate of toxicity-driven regimen
substitutions compared with AZT and d4T, an observation
that is consistent with both trial data and evidence from routine
programs.
11–13 TDF-based ART generated higher life years
and QALYs than AZT- or d4T-based options.
Some caution is required in the interpretation of cost-
effectiveness results. If the budget were to stay constant, our
results suggest that health would be maximized through
providing TDF-based ART concurrently with d4T-based ART
within this rural Lesotho context. Anticipated price reductions
in TDF would improve the cost-effectiveness of TDF-based
ART, with the implication that a greater proportion of those in
need would haveaccess to this superior treatment. On the other
hand, if the HIV-related budget can be increased, then the TDF
ICER could be used by policymakers to judge the relativecost-
effectiveness of TDF in comparison with other potential
usages of these funds in ﬁrst-line ART.
Our ﬁndings are not readily comparable with other
estimates as there are few published studies in the current
literature on the use of TDFin resource-poor settings. A cohort
study from Zambia showed similar low rates of toxicity but no
difference in outcomes, although it was noted that their TDF
cohort started with more advanced disease and follow-up time
was short. A cost analysis of switching from d4T to TDF in
this program showed an average cost increase of between US
$105 and US $206 per patient-year in care. Health-related
quality of life and cost-effectiveness were not, however,
presented.
14 In a recent report from Burma,
15 where TDF was
introduced in a privately funded program, the annual cost of
providing ART care with TDF was estimated at US $276 per
patient per year with observed advantages of simpliﬁcation in
their service delivery. A study from Spain
16 comparing
TDF/emtricitabine versus AZT/3TC using clinical data for
both effectiveness and tolerability found that TDF/emtricita-
bine had a lower ICER than AZT/3TC. Other studies on cost-
effectiveness of TDF have used models based on parameters
drawn from the literature to estimate costs and outcomes.
6,7
One such study from South Africa estimated that the price
of TDF would need to fall by 64% to achieve cost neutrality
in comparison with d4T. However, this study included far
higher unit costs (including TDF prices) and high levels of
secondary care services that are not normally available in
resource-poor settings.
7
Strengths of our study include the fact that our costs are
based on primary health care utilization, costing, and clinical
event data from a routine program in a rural setting, and can
thus be considered to provide a more accurate estimation of
actual costs to providers in similarly resourced settings. There
are several limitations inherent to observational studies. First,
clinical events such as mortality, loss to follow-up, and toxicity
could be subject to confounding. We did not adjust for
confounders in our event rate allocation for this study, but in
a separate multivariate analysis that assessed the hazard of
TABLE 3. Costs, Outcomes, and Incremental Cost-Effectiveness Ratios, by First-Line ART Option
d4T Based AZT Based TDF Based
Composition of regimen 93% d4T 1% d4T 1% d4T
3% AZT 96% AZT 22% AZT
0% TDF 3% TDF 77% TDF
Cost per patient-year (mean, 95% UI) 261.92 (254.96–268.89) 323.07 (317.07–329.15) 345.42 (341.25–349.61)
Life years per patient-year (mean) 0.83 0.86 0.90
QALYs per patient-year (mean) 0.79 0.86 0.89
ICER* (life years) (mean, 95% UI) N/A Weakly dominated 1193 (1153–1233)
ICER (QALYs) (mean, 95% UI) N/A Weakly dominated 835 (807–863)
*The ICER summarizes the ratio of the difference in costs to the difference in outcomes after eliminating weakly dominated options. The latter occurs when an option has a higher
ICER than a more effective strategy.
N/A, not available.
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events by drug was similar to those described in this study.
13
Potential for underreporting of adverse events due to the
simpliﬁed approach to ART delivery in rural Lesotho is
possible. However, the limitations of this setting reﬂect the
reality of many high-HIV burden, resource-limited settings
and the fact that this program was supported by clinicians
experienced in HIV/TB care meant that this program received
greater clinical oversight than many rural programs, giving us
conﬁdence that adverse event underreporting was unlikely.
Possible limitations due to the duration of the study (median
duration on ART being 508 days) also need to be considered.
However, a recent 3-country study reported that the median
time to toxicity was 141 days for d4T, 81 days for AZT, and 58
days for TDF.
17 The risk of longer-term adverse events are
mostly associated with d4T, suggesting therefore that adverse
events associated with d4T may have been underestimated
in our study.
18
A further limitation of this study is that HRQoL was
estimated by clinical staff using a visual analog scale,
instead of alternative methods that might be preferred in
health economics such as the standard gamble or the time
trade-off (see details in Supplemental Digital Content 4,
http://links.lww.com/QAI/A200).
9 Many of the resulting
HRQoL values were lower than found in another study.
7
However, values in the latter study were either estimated using
clinical experience or were taken from developed country
studies and from different diseases (eg, peripheral neuropathy
of the foot in diabetes patients). This suggests that additional
research is needed to better understand the impact of side
effects on HRQoL. We have adjusted for the uncertainty
associated with these HRQoL measures by reporting outcomes
as life years.
To facilitate implementation of TDF, political pressure
should be exerted, supported by a clear demand from countries,
to encourage further price reductions and additional generic
manufacturing. Barely 10 years ago, it seemed unlikely that HIV
would be treatable in sub-Saharan Africa due to the complexity
of treatment and the cost of all ARVoptions. However, thanks to
generic production, thecost of the most commonlyusedﬁrst-line
regimen (d4T/3TC/NVP) has fallen from US $281 to US $61
per patient per year.
3ThepriceofTDF/3TC/EFVhasfallenfrom
US $426 to US $173 per patient per year in the last 4 years
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while new synthesis processes and dose optimization studies
suggest potential for further reductions in the price of TDF and
partner drugs such as EFV . These efforts should be met by a ﬁrm
commitment from donors and implementers to ensure that
supply is met by a clear demand.
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